基因修饰乳酸乳球菌作为药物发送载体系统治疗黑色素瘤初探

发布时间：2018-05-13 11:43

本文选题：肿瘤靶向 + 乳酸乳球菌　；参考：《生物技术》2015年02期

【摘要】：[目的]探讨携带自杀基因单纯疱疹病毒胸苷激酶(HSV-tk)的重组乳球菌静脉注射后靶向实体肿瘤组织定殖及联合更昔洛韦(GCV)治疗小鼠黑色素瘤的可能性。[方法]荷瘤小鼠静脉注射乳球菌3d或7d后,将小鼠脾肺肝肾器官和肿瘤组织细胞匀浆后涂布于筛选培养基上,以乳酸菌数量的评价静脉发送乳球菌靶向定殖肿瘤细胞的可能性。以携带HSVtk的重组乳酸乳球菌经静脉途径处理荷瘤小鼠后,通过观测小鼠肿瘤体积变化及小鼠存活率评价相关抗肿瘤效果。[结果]静脉注射乳酸乳球菌3d后在小鼠脾肺肝肾和肿瘤组织内均有乳球菌检出,而7d后仅在肿瘤组织中发现有乳酸乳球菌的分布。与对照相比,静脉注射LL-HSV-tk联合GCV处理能显著抑制小鼠体内肿瘤的生长。[结论]静脉发送携带治疗性分子的乳酸乳球菌能靶向实体肿瘤组织定殖并抑制肿瘤的生长。
[Abstract]:[objective] to investigate the possibility of recombinant Lactococcus carrying herpes simplex virus thymidine kinase (HSV-tk) in the treatment of murine melanoma after intravenous injection targeting solid tumor tissue colonization and combined with ganciclovir (GCVV). [methods] after intravenous injection of Lactococcus in tumor-bearing mice for 3 days or 7 days, the homogenate of spleen, lung, liver and kidney organs and tumor tissue cells were coated on the screening medium. The possibility of targeting tumor cells of Lactococcus venosus was evaluated by the number of lactic acid bacteria. The tumor-bearing mice were treated with recombinant Lactococcus lactis carrying HSVtk via intravenous route. The tumor volume changes and survival rate of mice were observed to evaluate the antitumor effect. [results] Lactococcus lactis were detected in mice spleen, lung, liver, kidney and tumor tissues 3 days after intravenous injection, but only in tumor tissues after 7 days. Compared with the control group, intravenous LL-HSV-tk combined with GCV significantly inhibited tumor growth in mice. [conclusion] Lactococcus lactis, which carries therapeutic molecules, can target solid tumor tissue colonization and inhibit tumor growth.
【作者单位】：新疆生物资源基因工程重点实验室新疆大学生命科学与技术学院;
【基金】：国家自然科学基金项目(“利用乳酸杆菌表达系统制备HPV粘膜疫苗”,No.30860265) 新疆生物资源基因工程重点实验室基金项目(“乳酸菌介导HSVtk抗肿瘤的研究”,No.XJDX0201-2012-02)资助
【分类号】：R739.5

【共引文献】